B7x-cellent — In the March 1, 2013 issue of the Journal of Immunology, Drs. Xingxing Zang, Yael Abadi, and Hyungjun Jeon report a role for the immune regulatory molecule B7x in promoting the spread of cancer (metastasis). B7x inhibits the immune response and increased levels on tumors in cancer patients has been associated with poor clinical outcomes and death. Using a mouse model of metastatic breast cancer, the researchers found that removal of B7x signaling enhanced the anti-tumor immune response, which resulted in a decrease in tumors and enhanced survival. Cancer is the leading cause of death worldwide and targeted treatments for metastasis are critical to improving survival. The findings suggest that blocking B7x could offer a therapy that harnesses the power of the immune response to treat metastatic cancers. In related news, the journal OncoImmunology has invited Dr. Zang to write an “Auto-Commentary” on this work, and the Department of Defense’s Prostate Cancer Research Program has selected Dr. Zang's cancer immunology research to be highlighted in its program materials that communicate buzz-worthy research to Congress and other stakeholders. Dr. Zang is assistant professor of microbiology and immunology. Dr. Jeon is a research fellow in the Zang lab, and Dr. Abadi is a Ph.D. student who successfully defended her thesis recently.
Posted on: Wednesday, March 06, 2013